Open Orphan secures study trial contract with mystery pharmaceutical company
Open Orphan | August 10, 2020
Pharmaceutical services company Open Orphan has scored a £4.0m contract with an unnamed top-three global pharmaceutical company to be the sponsor of and provide a respiratory syncytial virus human challenge study trial. Open Orphan said the new contract represented the continued conversion of its substantial pipeline and generation of significant cash flow. The AIM-listed group added that the study would take place in subsidiary hVIVO's London-based quarantine unit and was expected to be completed by the end of the first quarter of 2021.